Biogen (BIIB) says that the final process for EC decision on Lecanemab's marketing authorisation is currently underway

01 Apr 2025 - 11:10- Equities- Source: Newswires

BIIB.USEquitiesBiogen Idec IncBIIBBiogen IncBiotechnologyBiotechnology (Group)Pharmaceuticals, Biotechnology & Life SciencesNASDAQ 100 IndexS&P 500 IndexEU SessionEU Session

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: